A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Filters
J.-C. Marquet, (dir.) – L'Europe, déjà, à la fin des temps préhistoriques
2007
Revue archéologique de l Ouest
Preserved Fulltext
Charles-Tanguy Le Roux L'ouvrage s'ouvre sur un chapitre introductif (ch. 1 : Présentation générale des sites), à la suite duquel les différents sites archéologiques sont présentés les uns après les autres ...
(ISBN 978-2-912610-11-9 ; 8 ).L'association en Région Centre pour l'Histoire et l'Archéologie a chargé Jean-Claude Marquet de réaliser, avec le soutien du programme Culture 2000 de l'Union européenne, ...
doi:10.4000/rao.482
fatcat:pmrfwxvrqzcezgpbhqjbydneam
Digital holography under non paraxial conditions
2018
Three-Dimensional Imaging, Visualization, and Display 2018
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
The knowledge of the exact complex (amplitude and phase) wavefield scattered for different illuminating beams allows the computation of the 3D spatial distribution of a specimen. This work looks on how diffraction tomography can behave under high numerical aperture focusing conditions. Scalar theory is no longer valid in such system and nonparaxial vectorial field theory must be used. 'Numerical methods such as FDTD techniques can also be used to investigate the interaction of this field with the specimen.
doi:10.1117/12.2307673
fatcat:fauu5rx2hvgmpeyzjbjrmxifea
Species dispersal and biodiversity in human-dominated metacommunities
2018
Journal of Theoretical Biology
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
The concept of the Anthropocene is based on the idea that human impacts are now the primary drivers of changes in the earth's systems, including ecological systems. In many cases, the behavior that causes ecosystem change is itself triggered by ecological factors. Yet most ecological models still treat human impacts as given, and frequently as constant. This undermines our ability to understand the feedbacks between human behavior and ecosystem change. Focusing on the problem of species
doi:10.1016/j.jtbi.2018.08.041
pmid:30176249
pmcid:PMC6161821
fatcat:zu5vejgzmbaivc36ymgqyihwe4
more »
... l, we evaluate the effect of dispersal on biodiversity in a system subject to predation by humans. People are assumed to obtain benefits from (a) the direct consumption of species (provisioning services), (b) the non-consumptive use of species (cultural services), and (c) the buffering effects of the mix of species (regulating services). We find that the effects of dispersal on biodiversity depend jointly on the competitive interactions among species, and on human preferences over species and the services they provide. We find that while biodiversity may be greatest at intermediate levels of dispersal, this depends on structure of preferences across the metacommunity.
A compilation flow for parametric dataflow
2014
Proceedings of the 2014 International Conference on Compilers, Architecture and Synthesis for Embedded Systems - CASES '14
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Efficient programming of signal processing applications on embedded systems is a complex problem. High level models such as Synchronous dataflow (SDF) have been privileged candidates for dealing with this complexity. These models permit to express inherent application parallelism, as well as analysis for both verification and optimization. Parametric dataflow models aim at providing sufficient dynamicity to model new applications, while at the same time maintaining the high level of
doi:10.1145/2656106.2656110
dblp:conf/cases/DardaillonMRMC14
fatcat:2mgcsosqlzejpdtvwyru5jasbm
more »
... y needed for efficient real life implementations. This paper presents a new compilation flow that targets parametric dataflows. Built on the LLVM compiler infrastructure, it offers an actor based C++ programming model to describe parametric graphs, a compilation front-end providing graph analysis features, and a retargetable back-end to map the application on real hardware. This paper gives an overview of this flow, with a specific focus on scheduling. The crucial gap between dataflow models and real hardware on which actor firing is not atomic, as well as the consequences on FIFOs sizing and execution pipelining are taken into account.The experimental results illustrate our compilation flow applied to compilation of 3GPP LTE-Advanced demodulation on a heterogeneous MPSoC with distributed scheduling features. This achieves performances similar to time-consuming hand made optimizations.
A New Compilation Flow for Software-Defined Radio Applications on Heterogeneous MPSoCs
2016
ACM Transactions on Architecture and Code Optimization (TACO)
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
It is derived from PinaVM [Marquet and Moy 2010], a front end for SystemC analysis. ...
Using slicing [Marquet and Moy 2010], we execute only the instructions required for the computation of this address. ...
doi:10.1145/2910583
fatcat:zvgvyrsahrbjlkretgonnbnbk4
Prostaglandin D2 amplifies lupus disease through basophil accumulation in lymphoid organs
2018
Nature Communications
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
C57BL/6J WT mice were purchased from Charles River Laboratories (L'Arbresle, France). ...
doi:10.1038/s41467-018-03129-8
pmid:29463843
pmcid:PMC5820278
fatcat:shuklfr3cnfwzl4h6phqcrhbqu
Approaching a state shift in Earth's biosphere
2012
Nature
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf.
Localized ecological systems are known to shift abruptly and irreversibly from one state to another when they are forced across critical thresholds. Here we review evidence that the global ecosystem as a whole can react in the same way and is approaching a planetary-scale critical transition as a result of human influence. The plausibility of a planetary-scale 'tipping point' highlights the need to improve biological forecasting by detecting early warning signs of critical transitions on global
doi:10.1038/nature11018
pmid:22678279
fatcat:5njlcgmbynefxh7d257frfro4i
more »
... as well as local scales, and by detecting feedbacks that promote such transitions. It is also necessary to address root causes of how humans are forcing biological changes.
A Detailed Power System Planning Model: Estimating the Long-Run Impact of Carbon-Reducing Policies
2015
2015 48th Hawaii International Conference on System Sciences
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2015; you can also visit the original URL.
The file type is application/pdf.
In this paper, a much more detailed representation of the nation's electricity system than has been traditionally used in policy models is employed. This detailed representation greatly increases the computational difficulty of obtaining optimal solutions, but is necessary to accurately model the location of new investment in generation. Given the proposed regulation of CO 2 emissions from US power plants, an examination of economically efficient policies for reducing these emissions is
doi:10.1109/hicss.2015.300
dblp:conf/hicss/ShawhanTZYMSSTT15
fatcat:5p6nvp2kqrggdgnd3oxcwlurci
more »
... d. The model incorporates realistic physical constraints, investment and retirement of generation, and price-responsive load to simulate the effects of policies for limiting CO 2 emissions over a twenty-year forecast horizon. Using network reductions for each of the three electric system regions in the U.S. and Canada, an optimal economic dispatch, that satisfies reliability criteria, is assigned for 12 typical hour-types in each year. Three scenarios are modeled that consider subsidies for renewables and either CO 2 emissions regulation on new investment or cap-and-trade. High and low gas price trends are also simulated and have large effects on prices of electricity but small impacts on CO 2 emissions. Low gas prices with cap-and-trade reduce CO 2 emissions the most; large subsidies for renewables alone do not reduce carbon emissions much below existing levels. Extensive retirement of coal-fired power plants occurs in all cases.
How to Improve Clinical Research Performances in France?
2008
The´rapie (Paris)
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf.
The general objective of this study was to proceed an inventory of measures which could help to improve the efficiency of clinical research in France. Method. Thanks to the discussion between the members of the round-table conference (composed of medical doctors (MD)/investigators; hospital managers; representatives of industrial promoters; general practitioners...), we have looked over the difficulties that meets clinical research in France nowadays. Results. We identified four fields of
doi:10.2515/therapie:2008046
pmid:18937908
fatcat:2nuhyhewobfxno4pqptqpnfmkm
more »
... : 1) availibility of resources for carrying out the trials in time and in quality; 2) feasability of the clinical trials, in their design and for the recruitment which depends on both of the investigation centers and patients (what is the image of human testing in the society?); 3) skills and motivation of all the elements of staffs in charge of clinical trials (MD; nurses; and the new jobs in medical research); 4) promptness and efficiency of the administrative organisation for a fast starting up of the trials. Conclusion. This study, which doesn't pretend to sufficiency, shows the gap of improvement for French clinical trials organisation.
Comment faire évoluer le paradigme du développement clinique et son découpage en phases I, II, III
2011
The´rapie (Paris)
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf.
Partant de la constatation que depuis 30 ans, le coût du développement augmente régulièrement à mesure que le nombre de nouvelles entités chimiques atteignant le marché décroît, comment faire des « économies » en termes de développement clinique, l'objectif étant un accès plus rapide au médicament, pour les besoins médicaux non couverts ? Plusieurs instruments existent pour permettre une mise à disposition plus rapide de produits innovants : les autorisations temporaires d'utilisation ou ATU
doi:10.2515/therapie/2011043
pmid:27392459
fatcat:4p2psijfezhbrhwaagorg2qdli
more »
... i ne sont pas concernées par ce travail), les autorisations de mise sur le marché (AMM) conditionnelles, les AMM sous circonstances exceptionnelles. Ces éléments sont repris dans la « road map » de l'Agence européenne du médicament, (European Medicines Agency ou EMA), qui dit : « A key issue for Regulators will be if a more "staggered" approval should be envisaged, characterised by a better defined/more restricted population of good responders, followed by a broadening of the population postauthorisation when more "real life" data are available. In addition, maximising the value of information generated in the post-authorisation phase should be developed through the use of cohorts and other prospectively collected use data, especially in the case of conditional marketing authorisations. » Le règlement intérieur de la Commission de transparence pour sa part prévoit la notion d'examen préliminaire : afin de préparer au mieux l'instruction des dossiers des produits présumés innovants et de limiter les délais, le bureau peut engager une étude préliminaire dès le dépôt du dossier au Comité des spécialités pharmaceutiques humaines (CHMP). Il peut à cette occasion solliciter de la firme des éléments d'information et faire appel à des experts externes. La mise en oeuvre de cette étude préliminaire n'exonère pas la firme de l'obligation de déposer un dossier complet. Les études post inscription demandées par la commission de transparence (ISPEP) le sont souvent dans le cas d'hésitations sur le niveau d'amélioration du service médical rendu ou ASMR (niveau II/III ou IV/V). Ces demandes concernent essentiellement des incertitudes sur la transposabilité, le profil patient ou le respect du bon usage. Parmi les études dont les résultats ont été rendus, dans 15 cas les résultats sont en conformité avec les attentes, dans 6 cas elles ont abouti à des réévaluations à la baisse, enfin dans 3 cas elles étaient non conclusives. Les recommandations finales de la Table Ronde étaient :
How to Improve the Clinical Development Paradigm and its Division into Phases I, II and III
2011
The´rapie (Paris)
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf.
Based on the observation that over the last 30 years the cost of development has risen regularly as the number of new chemical entities reaching the market has fallen, how can "savings" be made in terms of clinical development, the objective being more rapid access to a drug for medical needs that are not covered? Several instruments exist to enable innovative products to be made available more quickly: temporary use authorisations, which are not concerned by this work (ATUs), conditional
doi:10.2515/therapie/2011046
pmid:21851796
fatcat:dbsojrlvgbbgjk5c2f3wr2zlva
more »
... ing authorisations (MAs) and MAs under exceptional circumstances. These aspects have been taken up in the European medicines agency (EMA)'s "Road Map", which states "A key issue for Regulators will be if a more "staggered" approval should be envisaged, characterised by a better defined/more restricted population of good responders, followed by a broadening of the population post-authorisation when more "real life" data are available. In addition, maximising the value of information generated in the post-authorisation phase should be developed through the use of cohorts and other prospectively collected use data, especially in the case of conditional marketing authorisations." The rules of procedure of the Transparency Commission for their part provide for the notion of preliminary examination: in order to prepare as best as possible the examination of dossiers of products assumed to be innovative and to limit delays, the office can undertake a preliminary study as soon as the dossier has been filed at the Committee for medicinal products for human use (CHMP). It may, at this time, request the firm to provide further information and may call on external experts. The implementation of this preliminary study does not exonerate the firm of the obligation of filing a complete dossier. The post inscription studies requested by the Transparency Commission (ISPEP -public health benefit and post-marketing studies) are usually requested in the case of hesitations regarding the level of improvement of the medical benefit (ASMR) [level II/III or IV/V]. Such requests mainly concern uncertainties regarding the transposability, the patient profile or correct usage in real life. Among the studies whose results were provided, in 15 cases the results were in line with expectations, in 6 cases they resulted in downward re-evaluations and the final 3 cases were inconclusive. The final recommendations of the round table were: c 2011 Société Française de Pharmacologie et de Thérapeutique Thérapie 2011 Juillet-août; 66 (4)
Comment améliorer les performances de la recherche clinique en France ?
2008
The´rapie (Paris)
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf.
Texte reçu le 15 juillet 2008 ; accepté le 30 juillet 2008 Mots clés : recherche clinique ; faisabilité ; qualification ; efficacité Résumé -L'objectif général de l'étude était d'identifier les mesures devant permettre d'améliorer la performance de la recherche clinique en France. Méthode. Grâce à la discussion entre les membres de la table-ronde (composée de médecins investigateurs ; responsables hospitaliers ; représentants de promoteurs industriels ; médecins généralistes...), nous avons
doi:10.2515/therapie:2008045
pmid:27392546
fatcat:2brja2ldkfhkjci5gd5pzd6gae
more »
... é en revue les difficultés que rencontrent la recherche clinique française aujourd'hui. Résultats. Nous avons identifié quatre champs d'action : 1) la disponibilité des ressources nécessaires à la conduite des protocoles de recherche (disponibilité en quantité et en temps, dans les délais les plus brefs) ; 2) la faisabilité, celle de l'essai dans le design de son protocole, celle du recrutement qui dépend à la fois du centre/équipe/réseau investigateur et des patients et de l'image qu'ils ont de l'expérimentation biomédicale ; 3) la qualification et la motivation des individualités et des métiers associés qui composent l'équipe conduisant les protocoles de recherche ; 4) la fluidité et l'efficacité de l'organisation administrative pour des temps préparatoires au démarrage des essais les plus réduits au profit du temps de réalisation de l'essai. Conclusion. Cette étude, qui n'a pas la prétention à l'exhaustivité, a montré l'ampleur des efforts pour améliorer l'organisation française d'essais cliniques.
Page 64 of Das Kunstwerk Vol. 1, Issue 10-11
[page]
1946
Das Kunstwerk
Preserved Fulltext
The Internet Archive has digitized a microfilm copy of this work. It may be possible to borrow a copy for reading.
Charles-Louis Philippe, der Verfasser wehmütiger und un- züchtiger Bücher, erklärte einmal über seinen Freund Mar- quet: „Er besigt einen Sinn für das Gleichgewicht und die Schwere der Dinge, die ihn vor ...
ALBERT MARQUET
Nach Bonnard starb in diesem Jahre ein zweiter franzö- sischer Maler von Bedeutung: Albert Marquet, Marquet schloß am 14. Juli 72jährig die Augen. ...
Rare Pathogenic Variants in Mitochondrial and Inflammation-Associated Genes May Lead to Inflammatory Cardiomyopathy in Chagas Disease
2021
Journal of Clinical Immunology
Preserved Fulltext
A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
Cardiomyopathies are an important cause of heart failure and sudden cardiac death. Little is known about the role of rare genetic variants in inflammatory cardiomyopathy. Chronic Chagas disease cardiomyopathy (CCC) is an inflammatory cardiomyopathy prevalent in Latin America, developing in 30% of the 6 million patients chronically infected by the protozoan Trypanosoma cruzi, while 60% remain free of heart disease (asymptomatic (ASY)). The cytokine interferon-γ and mitochondrial dysfunction are
doi:10.1007/s10875-021-01000-y
pmid:33660144
pmcid:PMC8249271
fatcat:qx4kuizbojaunhtvmnqom6gwum
more »
... nown to play a major pathogenetic role. Chagas disease provides a unique model to probe for genetic variants involved in inflammatory cardiomyopathy.
Page 161 of La Revue de Paris Vol. 58, Issue 10
[page]
1951
La Revue de Paris
Preserved Fulltext
The Internet Archive has digitized a microfilm copy of this work. It may be possible to borrow a copy for reading.
Charles-Louis Philippe, Georges Besson, Léon Werth, Francis Jourdain avaient tracé déjà du « peintre de Paris » de forts beaux por-
1. Marquet (Éditions R. Laffont). ...
. — Albert Marquet souriait, mais ne parlait pas. ...
« Previous
Showing results 1 — 15 out of 1,180 results